menu
    • menu
    [{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Candid Therapeutics","amount2":0.32000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.32000000000000001,"dosageForm":"Oral","sponsorNew":"Candid Therapeutics \/ Candid Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Candid Therapeutics \/ Candid Therapeutics"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"EpimAb Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Candid Therapeutics","amount2":1,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":1,"dosageForm":"Oral","sponsorNew":"Candid Therapeutics \/ Candid Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Candid Therapeutics \/ Candid Therapeutics"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Financing","leadProduct":"CND106","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Candid Therapeutics","amount2":0.37,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.37,"dosageForm":"Undisclosed","sponsorNew":"Candid Therapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Candid Therapeutics \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Candid Therapeutics","amount2":0.93000000000000005,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.93000000000000005,"dosageForm":"Undisclosed","sponsorNew":"Candid Therapeutics \/ Candid Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Candid Therapeutics \/ Candid Therapeutics"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"AB Studio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Candid Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Candid Therapeutics \/ Candid Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Candid Therapeutics \/ Candid Therapeutics"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"CND261","moa":"CD20 | CD3","graph1":"Immunology","graph2":"Phase I","graph3":"Candid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Candid Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Candid Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Cizutamig","moa":"BCMA\/CD3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Candid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Candid Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Candid Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Candid Therapeutics

    Menu

    Candid Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Candid Therapeutics

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Candid Therapeutics

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CND261

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis

                            Details : CND261 is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Arthritis, Rheumatoid.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 04, 2025

                            Lead Product(s) : CND261

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Candid Therapeutics

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Candid Therapeutics

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cizutamig

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Candid Moves T-Cell Engagers Into Trials for Five Autoimmune Diseases

                            Details : Cizutamig is a bispecific antibody designed to simultaneously bind B-cell maturation antigen on B-cells and CD3 on T-cells, enabling T-cell–mediated cytotoxicity against BCMA-expressing B-cells.

                            Product Name : CND106

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            June 20, 2025

                            Lead Product(s) : Cizutamig

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Candid Therapeutics

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Candid Therapeutics

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Recipient : WuXi Biologics

                            Deal Size : $925.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Candid Steps up TCE Deal Momentum with $925M WuXi Partnership

                            Details : Under the agreement, Candid will have exclusive global rights to a tri-specific T-cell Engager discovered by the WuXi Biologics platform for treating autoimmune and inflammatory diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 06, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Recipient : WuXi Biologics

                            Deal Size : $925.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Candid Therapeutics

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Candid Therapeutics

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Recipient : Nona Biosciences

                            Deal Size : $320.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nona Biosciences, Candid Collaborate on Next-Gen T-Cell Engager Discovery Projects

                            Details : Nona's collaboration with Candid aims to advance the discovery of next-generation TCEs (T-cell engagers) focused on treating autoimmune diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 16, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Recipient : Nona Biosciences

                            Deal Size : $320.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Candid Therapeutics

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Candid Therapeutics

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery

                            Recipient : EpimAb Biotherapeutics

                            Deal Size : $1,000.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Candid, EpimAb Collaborate on T-Cell Engagers for Autoimmune Disease Treatments

                            Details : The companies have entered a strategic research collaboration to discover and develop novel T-cell Engager program candidates for various autoimmune indications.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 16, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery

                            Recipient : EpimAb Biotherapeutics

                            Deal Size : $1,000.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Candid Therapeutics

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Candid Therapeutics

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery

                            Recipient : AB Studio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Candid and Ab Studio Collaborate on T Cell Engagers for Autoimmune Disorders

                            Details : The companies entered a strategic research collaboration to discover and develop novel T Cell Engager program candidates for various autoimmune indications.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 16, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery

                            Recipient : AB Studio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Candid Therapeutics

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Candid Therapeutics

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CND106

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Venrock Healthcare Capital Partners

                            Deal Size : $370.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Candid Therapeutics Raises $370M to Evaluate Autoimmune Therapies Clinically

                            Details : CND106 is a BCMAxCD3 bispecific antibody designed to target and eliminate later stage B-cells which are responsible for producing harmful autoantibodies.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            September 09, 2024

                            Lead Product(s) : CND106

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Venrock Healthcare Capital Partners

                            Deal Size : $370.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth